492 related articles for article (PubMed ID: 31236626)
21. TspanC8 Tetraspanins and A Disintegrin and Metalloprotease 10 (ADAM10) Interact via Their Extracellular Regions: EVIDENCE FOR DISTINCT BINDING MECHANISMS FOR DIFFERENT TspanC8 PROTEINS.
Noy PJ; Yang J; Reyat JS; Matthews AL; Charlton AE; Furmston J; Rogers DA; Rainger GE; Tomlinson MG
J Biol Chem; 2016 Feb; 291(7):3145-57. PubMed ID: 26668317
[TBL] [Abstract][Full Text] [Related]
22. Multiple non-catalytic ADAMs are novel integrin α4 ligands.
Wang L; Hoggard JA; Korleski ED; Long GV; Ree BC; Hensley K; Bond SR; Wolfsberg TG; Chen J; Zeczycki TN; Bridges LC
Mol Cell Biochem; 2018 May; 442(1-2):29-38. PubMed ID: 28913673
[TBL] [Abstract][Full Text] [Related]
23. A disintegrin and metalloproteinase (ADAM)-mediated ectodomain shedding of ADAM10.
Parkin E; Harris B
J Neurochem; 2009 Mar; 108(6):1464-79. PubMed ID: 19183255
[TBL] [Abstract][Full Text] [Related]
24. Who decides when to cleave an ectodomain?
Hartmann M; Herrlich A; Herrlich P
Trends Biochem Sci; 2013 Mar; 38(3):111-20. PubMed ID: 23298902
[TBL] [Abstract][Full Text] [Related]
25. ADAM-Integrin Interactions: potential integrin regulated ectodomain shedding activity.
Bridges LC; Bowditch RD
Curr Pharm Des; 2005; 11(7):837-47. PubMed ID: 15777238
[TBL] [Abstract][Full Text] [Related]
26. Differential surface expression of ADAM10 and ADAM17 on human T lymphocytes and tumor cells.
Ebsen H; Schröder A; Kabelitz D; Janssen O
PLoS One; 2013; 8(10):e76853. PubMed ID: 24130797
[TBL] [Abstract][Full Text] [Related]
27. The ADAMs family of proteases as targets for the treatment of cancer.
Mullooly M; McGowan PM; Crown J; Duffy MJ
Cancer Biol Ther; 2016 Aug; 17(8):870-80. PubMed ID: 27115328
[TBL] [Abstract][Full Text] [Related]
28. Role of ADAMs in the ectodomain shedding and conformational conversion of the prion protein.
Taylor DR; Parkin ET; Cocklin SL; Ault JR; Ashcroft AE; Turner AJ; Hooper NM
J Biol Chem; 2009 Aug; 284(34):22590-600. PubMed ID: 19564338
[TBL] [Abstract][Full Text] [Related]
29. ADAMs family in kidney physiology and pathology.
Zhu H; Wang J; Nie W; Armando I; Han F
EBioMedicine; 2021 Oct; 72():103628. PubMed ID: 34653870
[TBL] [Abstract][Full Text] [Related]
30. Endocytosis of the non-catalytic ADAM23: Recycling and long half-life properties.
Souza ILM; Oliveira NH; Huamaní PAM; Martin AS; Borgonovo ZLM; Nakao LS; Zanata SM
Exp Cell Res; 2021 Jan; 398(2):112415. PubMed ID: 33296662
[TBL] [Abstract][Full Text] [Related]
31. The alpha secretase ADAM10: A metalloprotease with multiple functions in the brain.
Saftig P; Lichtenthaler SF
Prog Neurobiol; 2015 Dec; 135():1-20. PubMed ID: 26522965
[TBL] [Abstract][Full Text] [Related]
32. Contribution of ADAM17 and related ADAMs in cardiovascular diseases.
Kawai T; Elliott KJ; Scalia R; Eguchi S
Cell Mol Life Sci; 2021 May; 78(9):4161-4187. PubMed ID: 33575814
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the contribution of different ADAMs to tumor necrosis factor alpha (TNFalpha) shedding and of the function of the TNFalpha ectodomain in ensuring selective stimulated shedding by the TNFalpha convertase (TACE/ADAM17).
Zheng Y; Saftig P; Hartmann D; Blobel C
J Biol Chem; 2004 Oct; 279(41):42898-906. PubMed ID: 15292243
[TBL] [Abstract][Full Text] [Related]
34. Differential expression of five members of the ADAM family in the developing chicken brain.
Lin J; Luo J; Redies C
Neuroscience; 2008 Nov; 157(2):360-75. PubMed ID: 18832016
[TBL] [Abstract][Full Text] [Related]
35. Expression patterns of the ADAMs in early developing chicken cochlea.
Lin J; Yan X; Wang C; Talabattula VA; Guo Z; Rolfs A; Luo J
Dev Growth Differ; 2013 Apr; 55(3):368-76. PubMed ID: 23496030
[TBL] [Abstract][Full Text] [Related]
36. Degradome of soluble ADAM10 and ADAM17 metalloproteases.
Scharfenberg F; Helbig A; Sammel M; Benzel J; Schlomann U; Peters F; Wichert R; Bettendorff M; Schmidt-Arras D; Rose-John S; Moali C; Lichtenthaler SF; Pietrzik CU; Bartsch JW; Tholey A; Becker-Pauly C
Cell Mol Life Sci; 2020 Jan; 77(2):331-350. PubMed ID: 31209506
[TBL] [Abstract][Full Text] [Related]
37. ADAM10, the rate-limiting protease of regulated intramembrane proteolysis of Notch and other proteins, is processed by ADAMS-9, ADAMS-15, and the gamma-secretase.
Tousseyn T; Thathiah A; Jorissen E; Raemaekers T; Konietzko U; Reiss K; Maes E; Snellinx A; Serneels L; Nyabi O; Annaert W; Saftig P; Hartmann D; De Strooper B
J Biol Chem; 2009 Apr; 284(17):11738-47. PubMed ID: 19213735
[TBL] [Abstract][Full Text] [Related]
38. A Disintegrin and Metalloproteinase (ADAM) and ADAM with thrombospondin motifs (ADAMTS) family in vascular biology and disease.
Zhong S; Khalil RA
Biochem Pharmacol; 2019 Jun; 164():188-204. PubMed ID: 30905657
[TBL] [Abstract][Full Text] [Related]
39. Endoglycan (PODXL2) is proteolytically processed by ADAM10 (a disintegrin and metalloprotease 10) and controls neurite branching in primary neurons.
Hsia HE; Tüshaus J; Feng X; Hofmann LI; Wefers B; Marciano DK; Wurst W; Lichtenthaler SF
FASEB J; 2021 Sep; 35(9):e21813. PubMed ID: 34390512
[TBL] [Abstract][Full Text] [Related]
40. The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Dehmel T; Janke A; Hartung HP; Goebel HH; Wiendl H; Kieseier BC
Neurobiol Dis; 2007 Mar; 25(3):665-74. PubMed ID: 17207628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
